The Quantellect read.As of Nov 19, 2026, 7 active firms cover Pyxis Oncology Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $5.00 to $19.00 (about 3.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $9.00 sits 534% above the current $1.42. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-0.86 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.00
+533.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $1.42 current
Highest Target$19.00
Average Target$9.00
Lowest Target$5.00
Detailed analyst forecasts for PYXS
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate PYXS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PYXS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.29 – $-0.16 · 4 analysts · -43% YoY
Next period, 4 analysts expect Pyxis Oncology Inc to earn $-0.21 a share (range $-0.29 – $-0.16), versus $-0.37 a year earlier. Full-year consensus is $-1.08, growing to $-0.86 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $19.4K, rising to $0 next year.
Top analysts covering Pyxis Oncology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PYXS.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$5.00+252.1% to target
Overall win rate
52%
+ Follow
#2
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$8.00+463.4% to target
Overall win rate
47%
+ Follow
#3
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$8.00+463.4% to target
Overall win rate
38%
+ Follow
#4
SW
Stephen Willey
Stifel · Rank #474
Buy
$7.00+393.0% to target
Overall win rate
29%
+ Follow
#5
Derek Archila
Wells Fargo · Rank #481
Buy
$19.00+1238.0% to target
Overall win rate
36%
+ Follow
PYXS stock forecast FAQ
What is PYXS's average 12-month price target?+
The 7 active firms with a live target average $9.00 for Pyxis Oncology Inc over the next 12 months, ranging from a $19.00 high to a $5.00 low, as of Nov 19, 2026.
Is PYXS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PYXS?+
The Street-high target is $19.00 (Wells Fargo), and the Street-low is $5.00 (RBC Capital). The average of all 7 active-firm targets is $9.00.
How many active Wall Street firms cover PYXS?+
7 active firms have a recognized rating on Pyxis Oncology Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PYXS?+
Among analysts who currently cover PYXS, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $5.00 target.
What is Pyxis Oncology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.29 – $-0.16) across 4 analysts. Full-year EPS is projected at $-1.08, rising to $-0.86 the following year.
How much revenue is Pyxis Oncology Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $19.4K, growing to $0 next year.
Have analysts been upgrading or downgrading PYXS lately?+
As of Nov 19, 2026, 7 of 7 active firms rate PYXS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PYXS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.